查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1618226

關節疼痛注射市場機會、成長動力、產業趨勢分析與預測 2024 - 2032

Joint Pain Injections Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 180 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年，全球關節止痛注射市場估值為36億美元，預計2024年至2032年將以7.7%的年複合成長率(CAGR)成長。的發展。市面上依注射類型分為透明質酸注射液、皮質類固醇注射液、富血小板血漿注射液。 2023年，透明質酸注射劑以64.8%的收入佔有率主導市場，預計在預測期內複合年成長率將達到7.9%。人口老化和創新產品的推出相結合預計將推動市場成長。

人們越來越喜歡能夠快速獲得臨床結果的微創手術，這進一步增加了對透明質酸注射的需求。這些注射劑主要用於治療膝骨關節炎，並因其透過稱為黏性補充的方法改善關節功能的能力而受到認可。關節疼痛注射市場也按關節類型分類，包括膝關節、肩肘關節、踝關節、髖關節以及其他關節。膝關節領域預計將經歷顯著成長，預測顯示在分析期間將達到 27 億美元。

這種激增主要是由於膝關節相關疾病的高盛行率造成的，特別是骨關節炎，其特徵是軟骨和骨骼逐漸惡化。作為老年人的常見疾病，骨關節炎會導致不適和活動受限。標準治療選擇通常包括物理治療、復健、非類固醇類抗發炎藥物和透明質酸黏稠補充，這強調了關節疼痛注射在控制這些病症中的重要性。從區域分析來看，北美地區在 2023 年佔據最大的市場佔有率，達到 47.4%，預計未來幾年將大幅成長。

市場範圍
開始年份 2023年
預測年份 2024-2032
起始值 36 億美元
預測值 72 億美元
複合年成長率 7.7%

這種主導地位主要歸因於關節炎和其他骨科疾病發病率的上升，以及先進治療方案的快速採用。老化人口中關節疾病的盛行率不斷上升，加上運動和事故造成的傷害增加，以及治療解決方案的持續創新，是推動該地區市場成長的重要因素。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 骨科疾病盛行率不斷上升
      • 技術進步
      • 膝蓋疼痛注射的需求不斷增加
      • 緩解關節疼痛和發炎的治療優勢
    • 產業陷阱與挑戰
      • 關節疼痛注射費用高
      • 與關節疼痛注射相關的副作用
  • 成長潛力分析
  • 技術景觀
    • 幹細胞療法
    • 微創手術
  • 管道分析
  • 監管環境
    • 美國
    • 歐洲
  • 未來市場趨勢
  • 關節疼痛流行病學情景
  • 報銷場景
  • 2023 年定價分析
  • 差距分析
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
    • 全球的
    • 北美洲
    • 歐洲
    • 亞太地區
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按注射類型，2018 年 - 2032 年

  • 主要趨勢
  • 玻尿酸注射液
  • 皮質類固醇注射
  • 富血小板血漿注射

第 6 章：市場估計與預測：按聯合類型，2018 年 - 2032 年

  • 主要趨勢
  • 膝蓋
  • 肩部和肘部
  • 腳踝和臀部
  • 其他接頭類型

第 7 章：市場估計與預測：依最終用途，2018 年 - 2032 年

  • 主要趨勢
  • 醫院
  • 診所
  • 其他最終用途

第 8 章：市場估計與預測：按地區分類，2018 年 - 2032 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 9 章：公司簡介

  • Anika Therapeutics, Inc.
  • Arthrex
  • Bioventus
  • Emcyte Corporation
  • Ferring BV
  • Lifecore Biomedical
  • OrthogenRx
  • Pacira BioSciences (Flexion)
  • Pfizer, Inc.
  • Sanofi SA
  • Stryker Corporation
  • Zimmer Biomet Holdings, Inc.
簡介目錄
Product Code: 5403

The Global Joint Pain Injections Market was valued at USD 3.6 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2032. The increasing elderly population and the rising incidence of orthopedic conditions drive this market's expansion. The market is divided by injection type into hyaluronic acid injections, corticosteroid injections, and platelet-rich plasma injections. In 2023, hyaluronic acid injections dominated the market with a 64.8% revenue share and are expected to experience a notable CAGR of 7.9% during the forecast period. The combination of an aging demographic and the introduction of innovative products is anticipated to boost market growth.

There is a growing preference for minimally invasive procedures that deliver rapid clinical outcomes, further enhancing the demand for hyaluronic acid injections. These injections are primarily used for treating knee osteoarthritis and are recognized for their ability to improve joint function through a method known as viscosupplementation. The joint pain injections market is also categorized by joint type, including knee, shoulder and elbow, ankle, and hip, as well as other joints. The knee segment is expected to experience significant growth, with projections indicating it will reach USD 2.7 billion during the analysis period.

This surge is largely driven by the high prevalence of knee-related disorders, particularly osteoarthritis, characterized by the gradual deterioration of cartilage and bone. As a common ailment among the elderly, osteoarthritis leads to discomfort and restricted mobility. Standard treatment options often include physical therapy, rehabilitation, non-steroidal anti-inflammatory drugs, and viscosupplementation with hyaluronic acid, underscoring the importance of joint pain injections in managing these conditions. In terms of regional analysis, North America held the largest market share at 47.4% in 2023, with substantial growth anticipated in the upcoming years.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$3.6 Billion
Forecast Value$7.2 Billion
CAGR7.7%

This dominance is primarily attributed to the rising incidence of arthritis and other orthopedic disorders, alongside the swift adoption of advanced treatment options. The growing prevalence of joint conditions among the aging population, in line with an increase in injuries from sports and accidents, as well as continuous innovation in therapeutic solutions, are vital factors driving market growth in this region.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing prevalence of orthopedic diseases
      • 3.2.1.2 Technological advancements
      • 3.2.1.3 Rising demand for knee pain injections
      • 3.2.1.4 Therapeutics advantages to relieve joint pain & inflammation
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of joint pain injections
      • 3.2.2.2 Side effects associated with joint pain injections
  • 3.3 Growth potential analysis
  • 3.4 Technological landscape
    • 3.4.1 Stem cell therapy
    • 3.4.2 Minimally invasive procedures
  • 3.5 Pipeline analysis
  • 3.6 Regulatory landscape
    • 3.6.1 U.S.
    • 3.6.2 Europe
  • 3.7 Future market trends
  • 3.8 Joint pain epidemiology scenario
  • 3.9 Reimbursement scenario
  • 3.10 Pricing analysis, 2023
  • 3.11 Gap analysis
  • 3.12 Porter's analysis
  • 3.13 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
    • 4.3.1 Global
    • 4.3.2 North America
    • 4.3.3 Europe
    • 4.3.4 Asia Pacific
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Injection Type, 2018 - 2032 ($ Mn and Units)

  • 5.1 Key trends
  • 5.2 Hyaluronic acid injections
  • 5.3 Corticosteroid injections
  • 5.4 Platelet rich plasma injections

Chapter 6 Market Estimates and Forecast, By Joint Type, 2018 - 2032 ($ Mn and Units)

  • 6.1 Key trends
  • 6.2 Knee
  • 6.3 Shoulder & elbow
  • 6.4 Ankle & hip
  • 6.5 Other joint types

Chapter 7 Market Estimates and Forecast, By End Use, 2018 - 2032 ($ Mn and Units)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Clinics
  • 7.4 Other End Use

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn and Units)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Anika Therapeutics, Inc.
  • 9.2 Arthrex
  • 9.3 Bioventus
  • 9.4 Emcyte Corporation
  • 9.5 Ferring B.V.
  • 9.6 Lifecore Biomedical
  • 9.7 OrthogenRx
  • 9.8 Pacira BioSciences (Flexion)
  • 9.9 Pfizer, Inc.
  • 9.10 Sanofi S.A.
  • 9.11 Stryker Corporation
  • 9.12 Zimmer Biomet Holdings, Inc.